miR-20a is an independent prognostic factor in colorectal cancer and is involved in cell metastasis

Molecular Medicine Reports

Volumn 10, Issue 1, 2014, Pages 283-291

  Zhang, Guang Jun ^a   Li, Yu ^a   Zhou, He ^a   Xiao, Hua Xu ^a   Zhou, Tong ^a  

^a AFFILIATED HOSPITAL OF NORTH SICHUAN MEDICAL COLLEGE   (China)

Author keywords

Colorectal cancer; Epithelial mesenchymal transition; Metastasis; miR 20a; Prognostic factor

Indexed keywords

MICRORNA 20A; SMAD PROTEIN; 3' UNTRANSLATED REGION; MICRORNA; MIRN20 MICRORNA, HUMAN; SMAD4 PROTEIN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; COLORECTAL CANCER; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; MUCOSA; POLYMERASE CHAIN REACTION; 3' UNTRANSLATED REGION; AGED; CELL MOTION; COLORECTAL TUMOR; GENETICS; INTESTINE MUCOSA; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SEQUENCE ALIGNMENT; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ADULT; AGED; BASE SEQUENCE; CELL LINE, TUMOR; CELL MOVEMENT; COLORECTAL NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; INTESTINAL MUCOSA; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SEQUENCE ALIGNMENT; SMAD4 PROTEIN;

EID: 84901458945     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2144     Document Type: Article

References (38)

1. Tenesa A and Dunlop MG: New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet 10: 353-358, 2009.
2. Yang IP, Tsai HL, Hou MF, et al: MicroRNA-93 inhibits tumor growth and early relapse of human colorectal cancer by affecting genes involved in the cell cycle. Carcinogenesis 33: 1522-1530, 2012.
3. Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428, 2009.
4. Thiery JP and Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7: 131-142, 2006. (Pubitemid 43278296)
5. Voulgari A and Pintzas A: Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 1796: 75-90, 2009.
6. Du C, Zhang C, Hassan S, et al: Protein kinase D1 suppresses epithelial-to-mesenchymal transition through phosphorylation of snail. Cancer Res 70: 7810-7819, 2010.
7. Spaderna S, Schmalhofer O, Hlubek F, et al: A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology 131: 830-840, 2006. (Pubitemid 44307069)
8. Yao D, Dai C and Peng S: Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation. Mol Cancer Res 9: 1608-1620, 2011.
9. Lee Y, Jeon K, Lee JT, et al: MicroRNA maturation: stepwise processing and subcellular localization. EMBO J 21: 4663-4670, 2002. (Pubitemid 34984353)
10. Lee Y, Ahn C, Han J, et al: The nuclear RNase III Drosha initiates microRNA processing. Nature 425: 415-419, 2003. (Pubitemid 37187272)
11. Lund E, Güttinger S, Calado A, et al: Nuclear export of microRNA precursors. Science 303: 95-98, 2004. (Pubitemid 38055779)
12. Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269, 2006.
13. Li C, Nguyen HT, Zhuang Y, et al: Comparative profiling of miRNA expression of lung adenocarcinoma cells in two-dimensional and three-dimensional cultures. Gene 511: 143-150, 2012.
14. Moriyama T, Ohuchida K, Mizumoto K, et al: MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol Cancer Ther 8: 1067-1074, 2009.
15. Bhaumik D, Scott GK, Schokrpur S, et al: Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene 27: 5643-5647, 2008.
16. Zhang G, Xia S, Tian H, et al: Clinical significance of miR-22 expression in patients with colorectal cancer. Med Oncol 29: 3108-3812, 2012.
17. Paterson EL, Kazenwadel J, Bert AG, et al: Down-regulation of the miRNA-200 family at the invasive front of colorectal cancers with degraded basement membrane indicates EMT is involved in cancer progression. Neoplasia 15: 180-191, 2013.
18. Zhang GJ, Xiao HX, Tian HP, et al: Upregulation of microRNA-155 promotes the migration and invasion of colorectal cancer cells through the regulation of claudin-1 expression. Int J Mol Med 31: 1375-1380, 2013.
19. Fan MQ, Huang CB, Gu Y, et al: Decrease expression of microRNA-20a promotes cancer cell proliferation and predicts poor survival of hepatocellular carcinoma. J Exp Clin Cancer Res 32: 21, 2013.
20. Chang Y, Liu C, Yang J, et al: MiR-20a triggers metastasis of gall-bladder carcinoma. J Hepatol 59: 518-527, 2013.
21. Fan X, Liu Y, Jiang J, et al: miR-20a promotes proliferation and invasion by targeting APP in human ovarian cancer cells. Acta Biochim Biophys Sin (Shanghai) 42: 318-324, 2010.
22. Huang G, Nishimoto K, Zhou Z, et al: miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. Cancer Res 72: 908-916, 2012.
23. Li JY, Zhang Y, Zhang WH, et al: Differential distribution of miR-20a and miR-20b may underly metastatic heterogeneity of breast cancers. Asian Pac J Cancer Prev 13: 1901-1906, 2012.
24. Yan H, Wu J, Liu W, et al: MicroRNA-20a overexpression inhibited proliferation and metastasis of pancreatic carcinoma cells. Hum Gene Ther 21: 1723-1734, 2010.
25. Chai H, Liu M, Tian R, et al: miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines. Acta Biochim Biophys Sin (Shanghai) 43: 217-225, 2011.
26. Yu G, Tang JQ, Tian ML, et al: Prognostic values of the miR-17-92 cluster and its paralogs in colon cancer. J Surg Oncol 106: 232-237, 2012.
27. Motoyama K, Inoue H, Takatsuno Y, et al: Over- and under-expressed microRNAs in human colorectal cancer. Int J Oncol 34: 1069-1075, 2009.
28. Massagué J and Chen YG: Controlling TGF-beta signaling. Genes Dev 14: 627-644, 2000.
29. Wang LH, Kim SH, Lee JH, et al: Inactivation of SMAD4 tumor suppressor gene during gastric carcinoma progression. Clin Cancer Res 13: 102-110, 2007. (Pubitemid 46121858)
30. Powell SM, Harper JC, Hamilton SR, et al: Inactivation of Smad4 in gastric carcinomas. Cancer Res 57: 4221-4224, 1997. (Pubitemid 27413428)
31. Miyaki M, Iijima T, Konishi M, et al: Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene 18: 3098-3103, 1999. (Pubitemid 29261230)
32. Maitra A, Molberg K, Albores-Saavedra J and Lindberg G: Loss of Dpc4 expression in colonic adenocarcinomas correlates with the presence of metastatic disease. Am J Pathol 157: 1105-1111, 2000.
33. Riggins GJ, Kinzler KW, Vogelstein B and Thiagalingam S: Frequency of Smad gene mutations in human cancers. Cancer Res 57: 2578-2580, 1997. (Pubitemid 27283760)
34. Deckers M, van Dinther M, Buijs J, et al: The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res 66: 2202-2209, 2006.
35. Valcourt U, Kowanetz M, Niimi H, et al: TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol Biol Cell 16: 1987-2002, 2005. (Pubitemid 40471965)
36. Levy L and Hill CS. Smad4 dependency defines two classes of transforming growth factor {beta} (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. Mol Cell Biol 25: 8108-8125, 2005. (Pubitemid 41263004)
37. Müller N, Reinacher-Schick A, Baldus S, et al: Smad4 induces the tumor suppressor E-cadherin and P-cadherin in colon carcinoma cells. Oncogene 21: 6049-6058, 2002.
38. Pohl M, Radacz Y, Pawlik N, et al: SMAD4 mediates mesenchymal-epithelial reversion in SW480 colon carcinoma cells. Anticancer Res 30: 2603-2613, 2010.